Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands
Robert Gerald Jan Moes,1 Eline L Huisman,1 Samuel JP Malkin,2 Barnaby Hunt2 1Novo Nordisk BV, Alphen aan den Rijn, Netherlands; 2Ossian Health Economics and Communications, Basel, SwitzerlandCorrespondence: Barnaby Hunt, Ossian Health Economics and Communications GmbH, Bäumleingasse 20, Basel, 4051, Switzerland, Tel +41 61 271 6214, Email hunt@ossianconsulting.comIntroduction: Achieving and maintaining glycemic control is the cornerstone of type 1 diabetes management, with the aim of reducing the incidence of diabetes-related complications over the long term. However, many individuals fail to... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Reihe/Periodikum: | ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 87-96 (2023) |
Verlag/Hrsg.: |
Dove Medical Press
|
Schlagwörter: | diabetes complications / glycemic control / health economics / netherlands / type 1 diabetes / Medicine (General) / R5-920 / Therapeutics. Pharmacology / RM1-950 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26802125 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doaj.org/article/7d81cffd3f774331aa0f08a6dc07845b |